圓美光電(08311.HK)預期2021財年淨虧約4000萬港元
格隆匯3月4日丨圓美光電(08311.HK)公吿,根據對集團未經審核綜合管理賬目初步評估,主要由於集團按公允價值計入損益金融資產(即其於Mobvoi的投資)於2021財年可能錄得重大公允價值虧損及2021財年的分銷及銷售開支較2020財年有所增加,預期集團可能錄得公司權益持有人應占綜合虧損由2020財年的約1688.3萬港元大幅增加至2021財年的約4000萬港元。
或許由於最近香港疫情情況日趨嚴峻,集團健康相關產品(包括2019冠狀病毒病快速抗原測試包,個人衞生及消毒產品)於截至2022年2月28日止兩個月的銷售收入,可能較2021年同期有重大的增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.